Almirall, S.a.
Clinical trials sponsored by Almirall, S.a., explained in plain language.
-
New hope for bald spots: drug trial targets severe hair loss
Disease control Recruiting nowThis study tests a new drug called LAD603 for adults with severe to very severe alopecia areata, a condition causing major hair loss on the scalp. About 136 people will receive either the drug or a placebo to see if it helps hair regrow and is safe. The main goal is to measure ch…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated May 26, 2026 08:50 UTC
-
New hope for painful skin condition: experimental drug LAD191 enters mid-stage trial
Disease control Recruiting nowThis study tests a new drug, LAD191, in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to see if LAD191 can reduce the number of inflamed lesions better than a placebo. Participants will receive ei…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug LAD106 put to the test in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug, LAD106, in 93 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease, but to gath…
Phase: PHASE1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated May 18, 2026 12:11 UTC